Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Sufia Safina"'
Autor:
Ilya Tsimafeyeu, Oxana Shatkovskaya, Sergei Krasny, Nurzhan Nurgaliev, Ilya Varlamov, Vladislav Petkau, Sufia Safina, Ruslan Zukov, Mikhail Mazhbich, Galina Statsenko, Sergey Varlamov, Olga Novikova, Igor Zaitsev, Pavel Moiseyev, Alexander Rolevich, Alesya Evmenenko, Irina Popova, Dilyara Kaidarova, Liubov Vladimirova
Publikováno v:
Cancer Reports, Vol 4, Iss 3, Pp n/a-n/a (2021)
Abstract Background Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study assessed real‐world data on the use of therapies in mRCC and over
Externí odkaz:
https://doaj.org/article/2f3fdafb12794e8ebeff801e78ecee6e
Autor:
Natalia Dengina, Timur Mitin, Sergey Gamayunov, Sufia Safina, Yuliya Kreinina, Ilya Tsimafeyeu
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
Background Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are neces
Externí odkaz:
https://doaj.org/article/541676ecaac74a43be18b600eb3890a0
Autor:
Arkadiy Klochikhin, Robert I. Haddad, Amichay Meirovitz, Sufia Safina, Irene Brana, Christophe Le Tourneau, Ravindra Uppaluri, Nancy Y. Lee, Ezra E.W. Cohen, Rebecca Chernock, William Westra, Hong Liu, Burak Gumuscu, Kimberly Benjamin, Douglas Adkins
Publikováno v:
European Journal of Surgical Oncology. 49:e9
Autor:
Koji Kawai, Satoshi Nagamori, Katherine M Bell-McGuinn, Cristiano Ferrario, Wen Pin Su, Isabel Syndikus, Aude Flechon, Georgios Gakis, Timothy Dudley Clay, Leticia Vazquez Cortés, Ronald de Wit, Florence Joly, Bozena Sikora-Kupis, Sergio Bracarda, Astra M. Liepa, Annemie Rutten, Daniel P. Petrylak, Su Peng Yeh, Annamaria Zimmermann, Sameera R. Wijayawardana, Mutsushi Kawakita, Siobhan Ng, Thean Hsiang Tan, Chikara Ohyama, Yu Jung Kim, Yuriy Golovko, Dimitrios Mavroudis, Jian Ri Li, Reinoud J. B. Blaisse, Mustafa Erman, Francesca Russo, Catherine Becht, Anghel Adrian Udrea, Robert Huddart, Syed A. Hussain, Fransiscus L.G. Erdkamp, Satoshi Fukasawa, Francesco Massari, Motohide Uemura, Boris Alekseev, Irfan Cicin, Se Hoon Park, Marcello Tucci, Lajos Géczi, Maureen J.B. Aarts, Yu Li Su, Fumimasa Fukuta, Hyo Jin Lee, Wolfgang Schultze-Seemann, Alexandra Drakaki, Hakan Harputluoglu, Xavier Garcia del Muro, Santhanam Sundar, Avivit Peer, Herlinde Dumez, William E. Lawler, Juan Ignacio Delgado Mignorance, Naveed Sarwar, Jeanny B. Aragon-Ching, Benjamin T. Herms, Fredrik Laestadius, Nobuaki Matsubara, Ivan Sinielnikov, Cora N. Sternberg, Hiroyuki Nishiyama, Piotr Tomczak, Brigitte Laguerre, Rebecca R. Hozak, Vasilis Karavasilis, Christina A. Schwentner, Hiroyuki Tsunemori, Masayoshi Nagata, Igor Bondarenko, Andrea Necchi, Yen Chuan Ou, Scott T. Tagawa, Constance Thibault, Richard A. Walgren, Akira Yokomizo, Evan Y. Yu, Alejo Rodriguez-Vida, Sufia Safina, Ulka N. Vaishampayan, János Révész, Aristotelis Bamias, Jae-Lyun Lee, Chien Liang Lin, Thomas W. Flaig, Roman Fomkin, Petr Alexandrovich Karlov, Joanna Wojcik-Tomaszewska, Junichi Inokuchi, Wataru Obara, Haralambos Kalofonos, John D. Hainsworth, Marc-Oliver Grimm, Thomas Eugene Lowe, Pablo Gajate Borau, Simon J. Crabb, Lisa Sengeloev, Junji Yonese, Simon Chowdhury, Elizabeth Jane Hovey, Daniel Castellano, Peter Istvan Acs, Chia-Chi Lin, Claudia Lorena Urzua Flores, Jean-Pascal Machiels, Kim N. Chi, Takahiro Osawa, Nobuo Shinohara, Daniel Kejzman, Günter Niegisch, David Sarid, Yuksel Urun, Yun Gyoo Lee, Oday Hamid, Alina Amalia Herzal, Michael Schenker, Eli Rosenbaum, Enrique Grande, Raya Leibowitz-Amit, Naoto Miyajima, Michiel S. van der Heijden, Shinichi Yamashita, Susanna Yee Shan Cheng, Kazuo Nishimura, Sun Young Rha, Thomas Powles, Hasan Şenol Coşkun, Jens Bedke, Ivor J. Percent, Christos Papandreou, James K. Schwarz, Masafumi Oyama, Giorgio V. Scagliotti, Chong-Xian Pan, Yoshihiko Tomita, Giampaolo Tortora, Stéphane Culine, Suet Lai Shirley Wong, Andrey Semenov, Jennifer L. Cultrera, Niels Viggo Jensen, Michael Stöckle, Katsuyoshi Hashine
Publikováno v:
Lancet Oncology, 21(1), 105-120. Lancet Publishing Group
The Lancet. Oncology, Vol. 21, no.1, p. 105-120 (2020)
Lancet oncology, 21(1), 105-120. Elsevier Science
lancet oncology, 21(1), 105-120. Lancet Publishing Group
The Lancet. Oncology, Vol. 21, no.1, p. 105-120 (2020)
Lancet oncology, 21(1), 105-120. Elsevier Science
lancet oncology, 21(1), 105-120. Lancet Publishing Group
Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary en
Autor:
Dariusz M. Kowalski, Keunchil Park, Vishal Boolell, Salma K. Jabbour, Steven M. Keller, Valeriy Breder, Amy Sanford, Nikolaj Frost, Baerin Houghton, A. Samkari, Martin Reck, Ki Hyeong Lee, Noemi Reguart, Hong Liu, Alex Martinez-Marti, Takefumi Komiya, Theodore Pollock, Jean Baptiste Paoli, Sufia Safina, Evgeny Levchenko
Publikováno v:
JAMA Oncol
IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment outcomes and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7609733e2099c09e1daaebba833b59f
https://europepmc.org/articles/PMC8446818/
https://europepmc.org/articles/PMC8446818/
Autor:
Liubov Yu Vladimirova, Sufia Safina, Vladislav Petkau, Dilyara Kaidarova, Ruslan Zukov, Ilya Varlamov, Pavel Moiseyev, Ilya Tsimafeyeu, Irina L. Popova, Mikhail Mazhbich, Sergei Krasny, A. Rolevich, Galina Statsenko, Alesya Evmenenko, Sergey Varlamov, Nurzhan Nurgaliev, Igor Zaitsev, Oxana Shatkovskaya, Olga Novikova
Publikováno v:
Cancer Reports, Vol 4, Iss 3, Pp n/a-n/a (2021)
Cancer Reports
Cancer Reports
Background Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study assessed real‐world data on the use of therapies in mRCC and overall survi
Autor:
Nurzhan Nurgaliyev, Ani Oganesyan, Anastasia Bondarenko, Sergei Krasny, Rustem Gafanov, Anna Semenova, Svetlana Anatolievna Protsenko, Kristina Zakurdaeva, Sufia Safina, Ilya Tsimafeyeu
Publikováno v:
Cancer immunology, immunotherapy : CII. 69(6)
Hepatitis C virus (HCV) interferes with activation of innate and adaptive immune responses. Theoretically, the efficacy and toxicity of immune checkpoint inhibitors in cancer patients infected with HCV may differ. Nevertheless, HCV was an exclusion c
Autor:
Baerin Houghton, Dariusz M. Kowalski, Issam Abdelkarim Alawin, Nicolaj Frost, Alex Martinez-Marti, Noemi Reguart, Amy Sanford, A. Samkari, Steven M. Keller, Jean-Baptiste Paoli, Vishal Boolell, Takefumi Komiya, Hong Liu, Salma K. Jabbour, Valeriy Breder, Sufia Safina, Ki Hyeong Lee, Evgeny Levchenko, Martin Reck, Keunchil Park
Publikováno v:
Journal of Clinical Oncology. 39:8512-8512
8512 Background: KEYNOTE-799 (NCT03631784) is an ongoing study of the anti‒PD-1 antibody pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in patients (pts) with unresectable, locally advanced stage III NSCLC. Prior results from
Autor:
Yuliya Kreinina, Natalia Dengina, Ilya Tsimafeyeu, Sufia Safina, Timur Mitin, Sergey Gamayunov
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
ESMO Open
ESMO Open
Background Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are neces
Autor:
Sufia Safina, Rebecca D. Chernock, Ezra E.W. Cohen, Stéphane Temam, Ramona F. Swaby, Nancy Y. Lee, Irene Brana, Joy Yang Ge, Arkadiy Klochikhin, Christophe Le Tourneau, Amichay Meirovitz, Robert I. Haddad, Ravindra Uppaluri, Douglas Adkins, William H. Westra, Cecilia Pinheiro
Publikováno v:
Cancer Research. 80:CT285-CT285
Background: In phase 2 studies (NCT02296684 and NCT02641093), neoadjuvant and adjuvant pembrolizumab demonstrated a pathological response (PR) and acceptable safety in patients with high-risk, resectable, LA HNSCC. KEYNOTE-689 (NCT03765918) is a rand